R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter
the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients
at an early stage of disease will be observed for 3 months after enrollment and then treated
with drug for 6 months.